Impact of von Willebrand Disease on Costs and Patient Outcomes - Featuring a Patient Perspective

https://www.pharmacytimes.org/on-demand/impact-of-von-willebrand-disease-on-costs-and-patient-outcomes-featuring-a-patient-perspective-enduring

Related Videos

Related Content

Advertisement

June 13th 2025

Is the Employer Health Care Tax Exclusion Safe? Kerris Willis Shares Insight From American Benefits Council

Giuliana Grossi

While the tax exclusion for employer-sponsored health care was not included in the House-passed reconciliation bill, it remains a revenue target for Congress, risking inclusion in the Senate's version.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 13th 2025

DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

Rose McNulty

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 13th 2025

Pediatric Atopic Dermatitis Linked to Allergy Development

Maggie L. Shaw

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

June 13th 2025

Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise

Christina Mattina

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.

Related Content

Advertisement

June 13th 2025

Is the Employer Health Care Tax Exclusion Safe? Kerris Willis Shares Insight From American Benefits Council

Giuliana Grossi

While the tax exclusion for employer-sponsored health care was not included in the House-passed reconciliation bill, it remains a revenue target for Congress, risking inclusion in the Senate's version.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 13th 2025

DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

Rose McNulty

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 13th 2025

Pediatric Atopic Dermatitis Linked to Allergy Development

Maggie L. Shaw

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

June 13th 2025

Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise

Christina Mattina

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.